Recommendations for the management of patients with homozygous familial hypercholesterolaemia: Overview of a new European Atherosclerosis Society consensus statement

Atherosclerosis Supplements

Volumn 15, Issue 2, 2014, Pages 26-32

  Bruckert, Eric ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Aortic stenosis; Familial hypercholesterolemia; Plamaphaeresis; Statin

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; EZETIMIBE; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIPOMERSEN; MONOCLONAL ANTIBODY; ROSUVASTATIN; HYPOCHOLESTEROLEMIC AGENT;

APHERESIS; ARTICLE; CARDIOVASCULAR DISEASE; CONSENSUS DEVELOPMENT; DIFFERENTIAL DIAGNOSIS; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; GENE THERAPY; GENETIC ANALYSIS; HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; LIVER TRANSPLANTATION; MEDICAL HISTORY; MEDICAL SOCIETY; PLASMAPHERESIS; ATHEROSCLEROSIS; COMPLICATION; EUROPE; GENETICS; HOMOZYGOTE; HYPERLIPOPROTEINEMIA TYPE II; PRACTICE GUIDELINE; PROCEDURES;

ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; BLOOD COMPONENT REMOVAL; EUROPE; HOMOZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; PRACTICE GUIDELINES AS TOPIC;

EID: 84908141164     PISSN: 15675688     EISSN: 18785050     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2014.07.004     Document Type: Article

References (20)

1. Harada-Shiba M., Arai H., Oikawa S., Ohta T., Okada T., Okamura T., et al. Guidelines for the management of familial hypercholesterolemia. J Atheroscler Thromb 2012, 19:1043-1060.
2. Goldberg A.C., Hopkins P.N., Toth P.P., Ballantyne C.M., Rader D.J., Robinson J.G., et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the national lipid association expert panel on familial hypercholesterolemia. J Clin Lipidol 2011, 5:133-140.
3. Bruckert E., Saheb S., Bonté J.R., Coudray-Omnés C. Daily life, experience and needs of persons suffering from homozygous familial hypercholesterolaemia: Insights from a patient survey. Atherosclerosis Supplements 2014, 15:46-51.
4. Cuchel M., Bruckert E., Ginsberg H.N., Raal F.J., Santos R.D., Hegele R.A., Kuivenhoven J.A., et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014, 35(32):2146-2157. for the European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolaemia.
5. Berge K.E., Tian H., Graf G.A., Yu L., Grishin N.V., Schultz J., et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 2000, 290:1771-1775.
6. Bhattacharyya A.K., Connor W.E. Beta-sitosterolemia and xanthomatosis. A newly described lipid storage disease in two sisters. J Clin Invest 1974, 53:1033-1043.
7. Kidambi S., Patel S.B. Sitosterolaemia: pathophysiology, clinical presentation and laboratory diagnosis. J Clin Pathol 2008, 61:588-594.
8. Pagon RA, Adam MP, Ardinger HH, Bird TD, Dolan CR, Fong CT, etal. editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014.
9. Raal F.J., Pilcher G.J., Panz V.R., van Deventer H.E., Brice B.C., Blom D.J., et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation 2011, 124:2202-2207.
10. Marais A.D., Raal F.J., Stein E.A., Rader D.J., Blasetto J., Palmer M., et al. A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. Atherosclerosis 2008, 197:400-406.
11. Gagné C., Gaudet D., Bruckert E., Ezetimibe Study Group Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002, 105:2469-2475.
12. Stein E.A., Strutt K., Southworth H., Diggle P.J., Miller E., He F.H.S.G. Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 2003, 92:1287-1293.
13. Lind S., Olsson A.G., Eriksson M., Rudling M., Eggertsen G., Angelin B. Autosomal recessive hypercholesterolaemia: normalization of plasma LDL cholesterol by ezetimibe in combination with statin treatment. J Intern Med 2004, 256:406-412.
14. Raal F.J., Santos R.D. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis 2012, 223:262-268.
15. Catapano A.L., Reiner Z., De Backer G., Graham I., Taskinen M.R., Wiklund O., et al. European Society of C and European Atherosclerosis S. ESC/EAS Guidelines for the management of dyslipidaemias the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011, 217:3-46.
16. McGowan M.P., Tardif J.C., Ceska R., Burgess L.J., Soran H., Gouni-Berthold I., et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One 2012, 7:e49006.
17. Raal F.J., Santos R.D., Blom D.J., Marais A.D., Charng M.J., Cromwell W.C., et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 375:998-1006.
18. Stein E.A., Dufour R., Gagne C., Gaudet D., East C., Donovan J.M., et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 2012, 126:2283-2292.
19. Cromwell W.C., Thomas G.S., Boltje I., Chin W., Davidson M. Safety and efficacy of mipomersen administered as add-on therapy in patients with hypercholesterolemia and high cardiovascular risk. J Clin Lipidol 2012, 6:291-292.
20. Cuchel M., Meagher E.A., du Toit Theron H., Blom D.J., Marais A.D., Hegele R.A., et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013, 381:40-46.